{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:53:45Z","timestamp":1760576025994,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clon.2022.09.046","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T01:13:32Z","timestamp":1664932412000},"page":"e473-e481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma"],"prefix":"10.1016","volume":"34","author":[{"given":"C.","family":"Le Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Evin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Crespel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Samaille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2022.09.046_bib1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2022.09.046_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.09.046_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1008215213739","article-title":"Carboplatin versus cisplatin in solid tumors: an analysis of the literature","volume":"9","author":"Lokich","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib5","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib7","doi-asserted-by":"crossref","first-page":"V450","DOI":"10.1093\/annonc\/mdz252.002","article-title":"Personalized treatment according to geriatric assessment in first-line recurrent and\/or metastatic (R\/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (Elderly head and Neck cancer) FIT and UNFIT trials","volume":"30","author":"Guigay","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","article-title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)","volume":"29","author":"Tahara","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12032-016-0822-0","article-title":"Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease","volume":"33","author":"Narveson","year":"2016","journal-title":"Med Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib10","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2008.17.0530","article-title":"Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck","volume":"27","author":"Stewart","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib11","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"Vermorken","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib12","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3109\/00016480802590451","article-title":"Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients","volume":"129","author":"Grau","year":"2009","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.clon.2022.09.046_bib13","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1200\/JCO.2019.37.15_suppl.6032","volume":"37","author":"Even","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.09.046_bib14","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"suppl. 5","key":"10.1016\/j.clon.2022.09.046_bib15","doi-asserted-by":"crossref","first-page":"S807","DOI":"10.1016\/j.annonc.2021.08.1322","article-title":"Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)","volume":"32","author":"Gruenwald","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522004551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522004551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:51:30Z","timestamp":1760543490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655522004551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0936655522004551"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2022.09.046","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2022.09.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}